TABLE 2.

Results of the interassay study with four ANCA assays

Patient group and ANCA patternNo. (%) of patients with ANCA patterns observed by the following assay:
InovaImmcoEuroimmunImmuno Concepts
ANA-negative UC patients (n = 79)
    Total ANCA43 (54.4)40 (50.6)31 (39.2)30 (38.0)
    Atypical P-ANCA34 (43.0)5 (6.3)23 (29.1)23 (29.1)
    P-ANCA6 (7.6)30 (38.0)8 (10.1)4 (5.1)
    C-ANCA3 (3.8)5 (6.3)0 (0.0)3 (3.8)
ANA-negative CD patients (n = 99)
    Total ANCA18 (18.2)23 (23.2)11 (11.1)11 (11.1)
    Atypical P-ANCA16 (16.2)9 (9.1)8 (8.1)9 (9.1)
    P-ANCA2 (2.0)10 (10.1)3 (3.0)1 (1.0)
    C-ANCA0 (0.0)4 (4.0)0 (0.0)1 (1.0)
Non-IBD gastrointestinal-disease control groups
    Irritable bowel syndrome/ diverticulosis patients without inflammation (n = 64)
        Total ANCA2 (3.1)3 (4.7)
        Atypical P-ANCA1 (1.6)1 (1.6)
        P-ANCA1 (1.6)2 (3.1)
        C-ANCA0 (0.0)0 (0.0)
    Celiac disease patients (n = 96)
        Total ANCA5 (5.2)4 (4.2)
        Atypical P-ANCA2 (2.1)2 (2.1)
        P-ANCA3 (3.1)2 (2.1)
        C-ANCA0 (0.0)0 (0.0)